옵션 체인은 다양한 행사가격과 만기일에 대한 Luminar Technologies의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Luminar Technologies에 대한 시장 심리를 평가합니다..

Luminar Technologies (NASDAQ:LAZR) 주식, 옵션 체인

Luminar Technologies

Luminar Technologies Inc is an automotive technology company ushering in a new era of vehicle safety and autonomy. It operates its business through the following segments: Autonomy Solutions and advanced Technologies and Services. The majority of revenue is earned from the Autonomy Solutions segment which engaged in the design, manufacturing, and sale of LiDAR sensors catering mainly to the OEMs in the automobile, commercial vehicle, robo-taxi, and adjacent industries and advanced Technologies and Services provides semiconductors and related components, as well as design, test and consulting services to the Autonomy Solutions segment and various third-party customers, including government agencies and defense contractors, in markets generally unrelated to autonomous vehicles.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

LAZR

SAVE

타이슨 푸드(NYSE:TSN)의 오늘 개장 전 분기 실적을 발표할 예정인데, 벤징가 프로의 데이터에 의하면 월가는 주당 39센트의 이익과 131.6억 달러의 매출을 나타낼 것으로 예상하고 다. 타이슨 푸드는 시간외 거래에서 0.1% 상승한 62.05달러에 거래됐다.

타이슨 푸드, 스피릿 항공 및 월요일에 주목해야 3개 주식

Luminar Technologies, Inc. - Class A Common Stock

Luminar Technologies Inc

Guidance

WK Kellogg Raises FY24 Adj. EBITDA Guidance; Sees FY24 Adj. EBITDA Growth Of 5%-6%

Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.72) by 11.11 percent. This is a 25.58 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $354.62 million which beat the analyst consensus estimate of $225.00 thousand by 157.51K percent. This is a 110.90K percent increase over sales of $319.47 thousand the same period last year.

Earnings Beats

APRE

Aprea Therapeutics Q3 EPS $(0.64) Beats $(0.72) Estimate, Sales $354.62M Beat $225.00K Estimate

Endeavor Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDR#NYSE">EDR</a>) reported quarterly sales of $2.03 billion which beat the analyst consensus estimate of $1.56 billion by 30.29 percent. This is a 51.12 percent increase over sales of $1.34 billion the same period last year.

Endeavor Q3 EPS From Cont. Ops $(0.44), Down From $(0.24) Last Year, Sales $2.03B, Up From $1.22B Prior Year

L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) reported quarterly earnings of $3.27. The company reported quarterly sales of $137.50 million which missed the analyst consensus estimate of $141.78 million by 3.02 percent. This is a 5.40 percent decrease over sales of $145.34 million the same period last year.

Earnings Misses

FSTR

L.B. Foster Q3 2024 GAAP EPS $3.27, Sales $137.50M Miss $141.78M Estimate

WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.26 by 19.23 percent. The company reported quarterly sales of $689.000 million which beat the analyst consensus estimate of $674.044 million by 2.22 percent. This is a 0.43 percent decrease over sales of $692.000 million the same period last year.

WK Kellogg Q3 2024 Adj. EPS $0.31 Beats $0.26 Estimate, Sales $689.000M Beat $674.044M Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Buy and maintains $100 price target.

Price Target

Reiteration

Analyst Ratings

KROS

HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target

HilleVax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.42) by 23.81 percent. This is a 35.8 percent increase over losses of $(0.81) per share from the same period last year.

HLVX

HilleVax Q3 EPS $(0.52) Misses $(0.42) Estimate

Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.40) by 15 percent. This is a 8.11 percent increase over losses of $(0.37) per share from the same period last year.

IMNN

Imunon Q3 2024 GAAP EPS $(0.34) Beats $(0.40) Estimate. Cash and Equivalents of $10.3M

Guidance
<ul>
<li>Q4 Consolidated Revenue expected to increase in the high-single digits</li>
<li>Full Year 2024 Consolidated Revenue expected to increase in the mid-single digits</li>
<li>Q4 Consolidated Adjusted EBITDA expected to be approximately $290 million, up approximately 39%</li>
<li>Full Year 2024 Consolidated Adjusted EBITDA expected to be approximately$750 million, up approximately 8%</li>
<li>Full Year 2025 Consolidated Revenue expected to be approximately flat in a non-political year</li>
<li>Full Year 2025 Consolidated Adjusted EBITDA3 expected to be approximately$770 million, up approximately 3% in a non-political year</li>
</ul>

IHRT

iHeartMedia Expects Q4 Revenue Growth Of High-Single Digits Vs $1.00B Est, Reiterated FY24 Revenue Growth Of Mid-Single Digits Vs $3.92B Est, FY25 Revenue Growth Of Approx Flat Vs $3.86B Est

Offerings

BYND

Beyond Meat Files To Offer And Sell Common Stock Having Offering Price Of Up To $20M From Time To Time Through Or To Sales Agent

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the industrials sector.
<h3 class="wp-block-heading">Copa Holdings, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPA#NYSE">CPA</a>)</h3>
<ul>
<li>Dividend Yield: 6.58%</li>
<li>TD Cowen analyst Thomas Fitzgerald maintained a Buy rating and cut the price target from $145 to $130 on Aug. 9. This analyst has an accuracy rate of 61%.</li>
<li>Deutsche Bank analyst Michael Linenberg maintained a Buy rating and slashed the price target from $145 to $130 on Aug. 8. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: Copa Holding will release third-quarter results on Nov. 20.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> latest CPA news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="922" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71.png" alt="" class="wp-image-634808" style="width:671px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71-768x697.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Genco Shipping &amp; Trading Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNK#NYSE">GNK</a>)</h3>
<ul>
<li>Dividend Yield: 9.54%</li>
<li>Stifel analyst Benjamin Nolan downgraded the stock from Buy to Hold and cut the price target from $26 to $17 on Oct. 23. This analyst has an accuracy rate of 69%.</li>
<li>B. Riley Securities analyst Liam Burke maintained a Buy rating and increased the price target from $27 to $30 on May 10. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Nov. 6, Genco Shipping &amp; Trading posted downbeat quarterly sales.</li>
<li>Benzinga Pro's real-time newsfeed alerted<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> to latest GNK news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72.png" alt="" class="wp-image-634809" style="width:706px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72-768x706.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Karat Packaging Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>)</h3>
<ul>
<li>Dividend Yield: 5.40%</li>
<li>Truist Securities analyst Jake Bartlett downgraded the stock from Buy to Hold rating and cut the price target from $34 to $28 on Aug. 9. This analyst has an accuracy rate of 77%.</li>
<li>Stifel analyst Michael Hoffman reiterated a Buy rating ad increased the price target from $30 to $32 on March 15. This analyst has an accuracy rate of 84%.</li>
<li>Recent News: On Nov. 6, Karat Packaging raised its quarterly dividend from 35 cents to 40 cents per share.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> trend in KRT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73.png" alt="" class="wp-image-634810" style="width:711px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73-768x702.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li>Jim Cramer: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Dividends

Wall Street's Most Accurate Analysts Spotlight On 3 Industrials Stocks With Over 5% Dividend Yields

Biotech

Health Care

General

QNRX

Quoin Had Approximately $10.3M In Cash, Cash Equivalents And Marketable Securities As Of Sept. 30, 2024. This Is Expected To Fund The Company's Operations Into Late 2025

Standard BioTools Inc.&nbsp;("Standard BioTools" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization.

Management

Standard BioTools Appoints Alex Kim As Chief Financial Officer, Effective November 11, 2024

OKLO

Oklo Says Department Of Energy And The Idaho National Laboratory Completed Environmental Compliance Process Addressing The DOE Requirements For Site Characterization At Fission Power Plant Site In Idaho

HC Wainwright &amp; Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) with a Buy and maintains $5 price target.

ABUS

HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target

WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported quarterly sales of $689.000 which missed the analyst consensus estimate of $674.044 million by 100.00 percent. This is a 100.00 percent decrease over sales of $692.000 million the same period last year.

WK Kellogg Q3 Sales $689.000 Miss $674.044M Estimate

Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.46) by 2.17 percent.

Quoin Pharmaceuticals Q3 2024 GAAP EPS $(0.47) Misses $(0.46) Estimate

MBX Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>) reported quarterly losses of $(2.78) per share. This is a 70.43 percent increase over losses of $(9.40) per share from the same period last year.

MBX Biosciences Q3 EPS $(2.78) Up From $(9.40) YoY

Jim Cramer expressed optimism about a resurgence in mergers and acquisitions (M&amp;A) with the incoming Trump administration. Cramer predicts a more lenient approach to M&amp;A approvals compared to the previous administration, which was known for its stringent antitrust scrutiny.
What Happened: Cramer highlighted that the regional banking sector could significantly benefit from increased M&amp;A activity, allowing banks to grow by acquiring smaller entities or merging to form larger &#8220;super regionals,&#8221; CNBC<a href="https://www.cnbc.com/2024/11/06/jim-cramer-market-for-mergers-and-acquisitions-is-back-under-trump.html"> reported</a> on Thursday.
"I am very confident in the idea that, under President Trump, M&amp;A's about to come back and come back bigly," he said. "Companies will no longer have to fear super-strict antitrust scrutiny, so long as they stay on the right side of our mercurial President elect."
He also suggested that antitrust regulations might be relaxed, potentially benefiting Big Tech companies that faced scrutiny under Biden&#8217;s appointees. However, Cramer warned that Trump&#8217;s personal views could still impact regulatory actions, referencing the 2017 attempt to block the AT&amp;T and Time Warner merger due to Trump&#8217;s issues with CNN.
Cramer noted that several prominent tech CEOs have publicly congratulated Trump, likely in anticipation of a more favorable regulatory environment.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/41763941/jim-cramer-blasts-super-micro-computers-earnings-better-at-exonerating-itself-than-selling-nvidi?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Blasts Super Micro Computer&#8217;s Earnings: &#8216;Better At Exonerating Itself Than Selling&#8217; Nvidia GPUs</a>
Why It Matters: The potential revival of M&amp;A under Trump&#8217;s administration aligns with <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41798981/jim-cramer-calls-trumps-return-to-white-house-a-huge-win-for-the-stock-market">Cramer&#8217;s earlier remarks</a> that Trump&#8217;s return to the White House is a &#8220;huge win for the stock market.&#8221; The election of President-elect Trump has brought relief to traders, who anticipate pro-business policies, lower taxes, and deregulation. 
This optimism has already led to record highs in U.S. markets. The market rally <a href="https://www.benzinga.com/markets/asia/24/11/41801023/us-futures-european-stocks-rally-post-trump-victory-while-crude-oil-and-gold-decline-global-markets">post-Trump victory</a> saw the Dow, S&amp;P 500, and Nasdaq surge, with expectations of economic growth under Trump&#8217;s leadership. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41764063/dogecoin-powers-to-7-month-high-as-investors-anticipate-musk-headed-doge-department-under-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin Powers To 7-Month High As Investors Anticipate Musk-Headed DOGE Department Under Trump</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Jim Cramer Hopes M&A To 'Come Back Bigly' Under Trump Administration

Oppenheimer analyst Jed Kelly upgrades Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) from Perform to Outperform and announces $6 price target.

Upgrades

SGHC

Oppenheimer Upgrades Super Group (SGHC) to Outperform, Announces $6 Price Target

Luminar: Darkest Before The Dawn

Luminar's Revenue Delays, Debt Renegotiations, And Looming Equity Dilution

Ouster: Another Market Overreaction

Ouster Q2: Why The Selloff Doesn't Add Up And Why $23 Per Share Remains A Target

LiDAR Quarterly Insights Q2 2024 Summary

Mobileye: Bright Future, But Intel Overhang Is A Problem

Luminar Technologies announces workforce reduction

LiDAR Battle: US Proposals Strengthen Ouster But Leave Consumer Sectors Exposed To Chinese Competition

Luminar: Balance Sheet And Competition Concerns Overwhelm Potential Upside

Top 10 most shorted stocks on Wall Street

AEVA

BLNK

BLUE

CPTN

HSAI

INVZ

KSCP

LIDR

MBLY

MVIS

NKLA

OUST

SEDG

SPCE

WOLF

Press Releases

Luminar Reports First Quarter 2024 Business Update and Financials

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Luminar Technologies, Inc. (NASDAQ: LAZR)

Luminar Launches Sentinel Software for Automakers

Luminar to Provide Q2'24 Business Update on August 6, 2024

Luminar Bolsters Balance Sheet & Reports Second Quarter 2024 Business Update

BestGrowthStocks.Com Issues a Comprehensive Analysis of Luminar Technologies and Proposed Trade Restrictions

LAZR, LGMK, RIME, REGRF: Leaders Report Latest Advances in AI Transformation, Rolex Watch Market, LiDAR, and HealthTech for Aging

Leaders in The News: BigBear.ai, Luminar, New World Solutions, Tevogen Bio

Luminar to Provide Q3'24 Business Update November 11th; Reminder for Stockholders Meeting October 30th

BBAI

CSE:NEWS

LGMK

REGRF

RIME

TVGN

Adient

Autoliv

Aptiv

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Hldgs

BorgWarner

Dana

Dorman Prods

ECARX Holdings Inc. - Class A Ordinary shares

ECARX Holdings

Fox Factory Hldg

Gentex

Garrett Motion

Holley

Hesai Group - American Depositary Share, each ADS represents one Class B ordinary share

Comments

Luminar Technologies

Luminar Technologies (LAZR) 옵션

Luminar Technologies (NASDAQ:LAZR) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌